Abstract. The purpose of the present study was to identify a potential biomarker that is more effective than those already available for the prognosis of non-small cell lung cancer (NSCLC) patients. The expression of never in mitosis gene A (NIMA)-related kinase 2 (NEK2), minichromosome maintenance complex component 7 (Mcm7) and Ki67 was evaluated in 270 NSCLC tissues using immunohistochemical and immunofluorescence techniques. Associations between protein expression and clinicopathological characters were assessed, and the impact on overall survival was analyzed. High levels of NEK2, Mcm7 and Ki67 expression were detected in 25.9, 35.2 and 24.4% of the NSCLC tissues. Overexpression of NEK2 was detected more frequently in cases with high T and N stages (P<0.0001 and P=0.011, respectively). Correlations were present between the expression of NEK2, Mcm7 and Ki67. Kaplan-Meier curves indicated that the patients with overexpressed NEK2, Mcm7 and Ki67 had a poorer overall survival time compared to those with low expression for all stages (P<0.0001). In particular, the patients with NEK2 overexpression had a poorer prognosis. Multivariate Cox regression analysis showed that NEK2, Mcm7 and Ki67 are independent prognostic indicators for NSCLC. In conclusion, the data indicate that compared with Mcm7 and Ki67, NEK2 may be a more effective tumor proliferation marker of poor prognosis for NSCLC patients, and that NEK2 may represent a novel potential target for NSCLC therapeutic intervention.
Introduction
Lung cancer is a highly lethal and extremely common cancer worldwide. A study of cancer statistics in 2011 reported that the overall 5-year survival rate of lung cancer patients was ~16% (1) . Non-small cell lung cancer (NSCLC), of which adenocarcinoma and squamous cell carcinoma account for the vast majority of cases, represents almost 80% of primary lung cancer cases (2) . Prediction of survival is mainly based on tumor stage. Even for patients diagnosed at stage I, the 5-year survival rate is <70% (3) . It is critically important to identify robust, sensitive and specific biomarkers for prognosis in NSCLC. Identification of novel biomarkers may enhance early detection and effective treatment.
Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) is a serine/threonine kinase located at the centrosome that functions by regulating centrosome cohesion and separation via the phosphorylation of its structural components. NEK2 exists in three forms, NEK2A, NEK2B and NEK2C, in mammalian cells (4) . It is known that the aberrant regulation of NEK2 activity can lead to aneuploid defects and the abnormal proliferation of cancer cells (5) . The majority of previous studies on NEK2 have been conducted in cell lines, but NEK2 has rarely been investigated in NSCLC (6) .
Numerous studies have shown that cellular proliferative activity may provide valuable information for the prognosis and clinical management of various types of tumors, including NSCLC (7) (8) (9) (10) (11) (12) . Minichromosome maintenance complex component 7 (Mcm7) and Ki67 are two well-known cell proliferation markers. The former is expressed during the G 1 to M phase of the cell cycle, and the latter appears in early G 1 and persists in the S phase (13, 14) . In the present study, the expression levels of Mcm7, Ki67 and novel cell proliferation marker NEK2 were examined in NSCLC tissues, and the prognostic ability of these three proteins was investigated and compared. and Ki67 was analyzed using contiguous slices. All tissue sections were immunohistochemically stained using the avidin-biotin-peroxidase method and then counterstained with hematoxylin (Shenyang Shuangding Pharmaceutical Co., Ltd., Shenyang, China). The staining was scored by three independent investigators without knowledge of patient outcomes. The sections were evaluated at low magnification (x100) to identify areas where NEK2, Mcm7 and Ki67 were evenly stained. The percentage of positively stained cells was calculated in >1, 000 tumor cells. The expression levels of Mcm7 and Ki67 were assessed by the labeling index, determined by counting the number of distinctly stained malignant cells, regardless of the intensity, divided by the total number of tumor cells. The two proteins were evaluated in the areas of highest positivity, and at least 1,000 tumor cells were counted. The average of the percentage of positive cells in the three scores represented the final score of the sample, yielding a continuous score from 0 to 100 for Mcm7 and Ki67. The expression of NEK2 was determined on the basis of staining intensity and the percentage of immunoreactive cells by reference to the immunoreactivity score (16) . Staining intensity was rated as follows: 0, negative; 1, weakly positive; 2, moderately positive; and 3, strongly positive. The average tumor cell staining intensity score multiplied by the percentage of positive cells represented a final score ranging from 0 to 300. All cases were divided into two groups, a strongly-positive group (score range, 50-100 for Mcm7 and Ki67; and 240-300 for NEK2). All cases with discrepancies were jointly re-evaluated by the investigators and a consensus was obtained.
Materials and methods

Clinical
Assessment and imaging of the immunohistochemistry was performed using a Leica DM2000 microscope equipped with Leica DFC Cameras-Image Acquisition System (software V3.5.0; Leica Microsystems, Heerbrugg, Switzerland).
Immunofluorescence. The sections were deparaffinized in xylene, rehydrated in graded alcohol series and boiled in 0.01 M citrate buffer (pH 6.0) for 2 min in an autoclave. Double immunof luorescence analysis was performed using rabbit polyclonal NEK2 antibody (1 to 200 dilution), mouse monoclonal Mcm7 antibody (1 to 200 dilution) and mouse monoclonal Ki67 antibody (1 to 200 dilution). Goat anti-rabbit (Alexa Fluor 488-labeled; Molecular Probes) and goat anti-mouse (Alexa Fluor 594-labeled; Molecular Probes, Invitrogen Life Technologies, Carlsbad, CA, USA) were used as the secondary antibodies. Fluorescence signals were analyzed by recording stained images using an Olympus FV1000 Laser Scanning Confocal Microscope (Olympus, Tokyo, Japan).
Statistical analysis. The data were subject to statistical analysis using the SPSS software package (version 13.0; SPSS, Inc., Chicago, IL, USA). The correlation between the expression of NEK2 and Mcm7/Ki67 and the clinicopathological parameters was tested by χ 2 test and bivariate analysis. Survival curves were calculated by the Kaplan-Meier product-limit estimate method and then examined using the log rank procedure. The significance of multiple predictors of survival was assessed by the Cox regression analysis. P<0.05 was considered to indicate a statistically significant difference. Survival analysis and prognostic significance of the expression of NEK2, Mcm7 and Ki67. The correlation between survival and the expression of NEK2, Mcm7 and Ki67 was evaluated in the 270 patients diagnosed with NSCLC. A significant difference was observed when the patient cohort was stratified by the level of the expression of NEK2, Mcm7 and Ki67. It was notable that the patients with NSCLC who had positive NEK2 and Mcm7/Ki67 expression had a lower survival rate than patients with NEK2-and Mcm7/Ki67-negative expression, indicating that NEK2 is a better prognostic factor than Mcm7/Ki67 (Fig. 3) . Multivariate Cox regression analysis showed NEK2 expression was an independent prognostic factor for overall survival in patients with NSCLC (hazard ratio, 2.234; 95% confidence interval, 1.104-4.523; P= 0.025), which was an improvement on the expression of Mcm7 (P=0.034) and Ki67 (P=0.026). However, the combined expression of NEK2 and Mcm7/Ki67 was an even more effective prognostic predictor (P<0.0001) (Table III) .
Results
Expression of NEK2, Mcm7 and
Discussion
During the past two decades, due to the histological and phonotypical heterogeneity of NSCLC, identification of more effective novel prognostic markers has become of vital importance in the selection of high-risk patients with NSCLC (15) . Effective genetic markers can further stratify NSCLC into effective treatment subgroups. Prognosis may improve with a focus on the molecular markers of risk, which may lead to improved detection or treatment strategies (17,18).
It is known that the majority of tumor cells in human malignancies exhibit centrosome abnormalities. The deregulation of centrosome function may be a major contributory factor to cancer cell proliferation and progression (19) . NEK2 is an important centrosome regulatory factor that was believed to be significant in finding a molecular mechanism for tumorigenesis and may now present a novel target for therapeutic intervention.
NEK2 is a serine/threonine kinase located at the centrosome and involved in mitotic regulation. NEK2 overexpression causes the induction of premature centrosome separation and Table I . Correlation between NEK2, Mcm7 and Ki67 expression and the clinicopathological features of NSCLC. nuclear defects, which are indicative of mitotic errors (20) . NEK2 is involved in cell division and proliferation and mitotic regulation by centrosome splitting (21, 22) . Previous studies have also found that NEK2 protein expression is elevated 2-5 fold in cell lines derived from a variety of human tumors, including those of the ovary, breast and prostate (23). The A B C D present study showed that NEK2 expression was significantly upregulated in NSCLC. NEK2 expression was found to be correlated with T stage and lymph node metastasis. We have also found significant upregulated NEK2 expression in human breast cancer (unpublished data), which is indicated similarly in another previous study (24) . The Mcm7 protein is a type of licensing protein that can regulate DNA replication and indicates the presence of cell proliferation. The protein family includes 6 subunits, with Mcm7 as one of them; in vivo and in vitro experiments showed that once any member of the protein family becomes inactivated or missed, DNA replication will be repressed. They also have duplicate activity and play a crucial role in duplicate fork elongation (25) (26) (27) (28) . Abnormal Mcm7 expression is observed in numerous tumor types and correlates with a poor prognosis. Fujioka et al previously showed that Mcm7 in the tissues of lung adenocarcinomas could have prognostic implications (29) . High MCM7 expression is also an adverse prognostic factor for overall survival in patients with Hodgkin lymphoma (HL) (30) . Moreover, increasing MCM7 expression was observed from normal to cervical intraepithelial neoplasia III (CIN III) samples, with the highest MCM7 expression values detected in CIN III cases (31) . Ki67 is a proliferation-associated nuclear antigen, whose expression can be observed in all cycling cells, with the exception of resting cells in the G 0 phase, and expressed in cells in the S/G 2 and M phase in particular. Ki67 has been widely identified as a parameter of tumor proliferation.
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The present study demonstrated that NEK2, Mcm7, Ki67 and their combined expression appears to be associated with a poorer prognosis in patients with NSCLC. These proteins are independent prognostic factors for survival in patients with resected NSCLC, however, compared with Mcm7 and Ki67, NEK2 is a more effective proliferative factor for NSCLC prognosis. Moreover, a significant correlation was observed between the expression of the three proteins and the clinical pathological features. These results indicated that NEKs, Mcms and Ki67 may be involved in a relevant pathway in the tumor cell proliferation process, which requires further study. To the best of our knowledge, no study has previously In summary, the present study data revealed that NEK2, Mcm7 and Ki67 may all be independent prognostic factors in patients with NSCLC. NEK2 is a better factor for determining the prognosis of NSCLC. The evaluation of NEK2 expression may provide useful information for doctors to make optimal clinical decisions, and may be a novel potential target for NSCLC therapy, which will require analysis by further validation studies. 
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